Download PDF
Dtsch Med Wochenschr 2001; 126(42): 1178-1182
DOI: 10.1055/s-2001-17892
Übersichten
© Georg Thieme Verlag Stuttgart · New York

Neue Indikationen für Thalidomid?

New indications for thalidomideG. Tuinmann, S. Hegewisch-Becker, D. K. Hossfeld
  • Klinik und Poliklinik für Innere Medizin; Abteilung Onkologie, Hämatologie (Dir.: Prof. Dr. med. D.K. Hossfeld), Universitätsklinikum Hamburg Eppendorf
Further Information

Publication History

Publication Date:
18 October 2001 (online)

Also available at
   Permissions and Reprints
Preview

Anfang der 60er Jahre wurde das als Sedativum und Hypnotikum eingesetzte Thalidomid mit dem Handelsnamen Contergan® vom Markt zurückgezogen, da es unter der Einnahme zu Missbildungen bei 6000 - 10 000 Neugeborenen gekommen war. Trotzdem wurden nachfolgend individuelle Behandlungsversuche mit Thalidomid bei Erkrankungen wie Lepra oder Morbus Behçet unternommen. Unter der Einnahme wurde immer wieder eine deutliche Symptomverbesserung beschrieben. Jüngere Veröffentlichungen zeigen, dass Thalidomid antineoplastische, antiangiogenetische und immunmodulatorische Wirkungen hat. Insbesondere therapierefraktäre multiple Myelome können erfolgreich behandelt werden. Derzeit wird die Wirkung von Thalidomid in zahlreichen prospektiven Studien bei verschiedenen Malignomen evaluiert. Der folgende Artikel soll diese Entwicklung darstellen, die Anwendungsmöglichkeiten nennen, aber auch auf die Grenzen und Gefahren dieser Behandlung hinweisen.

Literatur

  • 1 Bahmer F A. Thalidomide treatment of recurrent erythema multiforme.  Acta Derm Venereol. 1982;  62 449-450
    Search in Google Scholar
  • 2 Barnhill R I, McDougal A C. Thalidomide: use and possible mode of action in reactional lepromatous leprosy and in various other conditions.  J Am Acad Dermatol. 1982;  7 317
    Search in Google Scholar
  • 3 Chen T L, Vogelsang G B, Petty B G. et al . Plasma pharmacokinetics and urinary excretion of thalidomide after oral dosing in healthy male volunteers.  Drug Metab Dispo. 1989;  17 402-405
    Search in Google Scholar
  • 4 D’Amato R J, Loughnan M S, Flynn E. et al . Thalidomide is an inhibitor of angiogenesis.  Proc Natl Acad Sci USA. 1994;  91 4082-4085
    Search in Google Scholar
  • 5 Dankbar B, Padro T, Leo R egine, Feldmann B, Kropff M, Mesters R M, Serve H, Berdel W E, Kienast J. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma.  Blood. 2000;  95 2630-2636
    Search in Google Scholar
  • 6 Eisen T, Boshoff C, Mak I. et al . Continuous low dose thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer.  Br J Cancer. 2000;  82 812-817
    Search in Google Scholar
  • 7 Fife K, Howard M R, Gracie F, Phillips R H, Bower M. Activity of thalidomide in AIDS-related Kaposi’s sarcoma and correlation with HHV8 titre.  Int J STD AIDS. 1998;  9 751-755
    Search in Google Scholar
  • 8 Fine H A, Figg W D, Jaeckle K, Wen P Y, Kyrithis A P, Loeffler J S, Levin V A, Black P M, Kaplan R, Pluda J M, Yung W KA. Phase II Trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas.  J Clin Oncol. 2000;  18 708-715
    Search in Google Scholar
  • 9 Florence A L. Is Thalidomide to blame.  Br Med J. 1960;  2 1954
    Search in Google Scholar
  • 10 Folkman J. Clinical applications of research on angiogenesis.  N Engl J Med. 1995;  333 1757-1763
    Search in Google Scholar
  • 11 Gad S M, Shannon E J, Krotoski W A. et al . Thalidomide induces imbalences in T-lymphocyte subpopulation in the circulating blood of healthy males.  Lepr Rev. 1985;  56 35-39
    Search in Google Scholar
  • 12 Geitz H, Handt S, Zwingenberger K. Thalidomide selectively modulates the density of cell surface molecules involved in the adhesion cascade.  Immunopharmacology. 1996;  31 213-221
    Search in Google Scholar
  • 13 Grabstahl H, Golbey R. Clinical experiences with thalidomide in patients with cancer.  Clin Pharmacol Ther. 1965;  6 298-302
    Search in Google Scholar
  • 14 Grosshans E, Illy G. Thalidomide therapy for inflammatory dermatoses.  Int J Dermatol. 1984;  23 598-602
    Search in Google Scholar
  • 15 Gutierrez-Rodriguez O, Starusta-Bacal P, Gutierrez-Montes O. Treatment of refractory rheumatoid arthritis-the thalidomide experience.  J Rheumatol. 1989;  16 158-163
    Search in Google Scholar
  • 16 Hallek M, Bergsnagel P L, Anderson K C. Multiple myeloma: increasing evidence for a multistep transformation process.  Blood. 1998;  91 3-21
    Search in Google Scholar
  • 17 Haslett P A, Corral L G, Albert M, Kaplan G. Thalidomide costimulates primary human t lymphocytes, preferentially inducing proliferation, cytokine production, and cytotoxic respones in the CD8+ subset.  J exp Med. 1998;  197 1885-1892
    Search in Google Scholar
  • 18 Haslett P A, Klausner J D, Makonkawkeyoon S, Moreira A, Metatratip P, Boyle B, Kunachiwa W, Maneekarn N, Vongchan P, Corral L G, Elbeik T, Shen Z, Kaplan G. Thalidomide stimulates T cell responses and interleukin 12 production in HIV-infected patients.  AIDS Res Hum Retroviruses. 1999;  15 1169-1179
    Search in Google Scholar
  • 19 Hellmann K, Duke D I, Tucker D F. Prolongation of skin homograft survival by thalidomide.  Br Med J. 1965;  18 687-689
    Search in Google Scholar
  • 20 Hideshima T, Chauhan D, Shima Y, Raje N, Davies F E, Tai Y T, Treon S P, Lin B, Schlossman R L, Richardson P, Mulier G, Stirling D I, Anderson K C. Thalidomide and its analogs overcome drugresistance of human mulötiple myeloma cells to conventional therapy.  Blood. 2000;  96 2943-2950
    Search in Google Scholar
  • 21 De Iongh R U. A quantitative ultrastructural study of motor and sensory lumbrosacral nerve roots in the thalidomide-treated rabbit fetus.  J Neurol Neuropathol Exp Neurol. 1990;  49 564-581
    Search in Google Scholar
  • 22 Jacobsen J M, Greenspan J S, Spritzler J, Ketter N, Fahey J L, Jackson J B, Fox L, Chernoff M, Wu A W, MacPhail L A, Vasquez G J, Wohl D A. National institute of allergy and infectious diseases AIDS clinical trial groups . Thalidomide for the treatment of oral aphtous ulcers in patients with human immunodeficiency virus infection.  N Engl J Med. 1997;  336 1487-1493
    Search in Google Scholar
  • 23 Juliusson G, Celsing F, Turesson I, Lenhoff S, Adriansson M, Malm C. Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma.  Br J Haematol. 2000;  109 89-96
    Search in Google Scholar
  • 24 Lenz W, Knapp K. Die Thalidomid-Embryopathie.  Dtsch Med Wochenschr. 1962;  87 1232-1242
    Search in Google Scholar
  • 25 Londono F. Thalidomide in the treatment of actinic prurigo.  Int J Dernatol. 1973;  12 326-328
    Search in Google Scholar
  • 26 Mascaro J M, Lecha M, Torras H. et al . Thalidomide in the treatment of recurrent, necrotic, and giant mucocutaneous aphthae and aphthosis.  Arch Dermatol. 1979;  115 636-637
    Search in Google Scholar
  • 27 McBride W G. Thalidomide and congenital abnormalities.  Lancet. 1961;  2 1358
    Search in Google Scholar
  • 28 McCarty M F. Thalidomide may impede cell migration in primates by down-regulating integrin beta-chains: potential therapeutic utility in solid malignancies, proliferative retinopathy, inflammatory disorders, neointimal hyperplasia, and osteoporosis.  Med Hypotheses Aug. 1997;  49 123-131
    Search in Google Scholar
  • 29 McHugh S M, Rifkin I R, Deighton J. et al . The immunosuppressive drug thalidomide induces T-helper cell Type 2 (Th2) and concomitantly inhibits Th1 cytokine production in mitogen- and antigen-stimulated human peripheral blood mononuclear cell cultures.  Clin Exp Immunol. 1995;  99 160-167
    Search in Google Scholar
  • 30 Mückter H, Moré E. Thalidomide and cancer.  Arzneimittelforschung. 1966;  16 129-134
    Search in Google Scholar
  • 31 Neubert R, Merker H J, Neubert D. Developmental model for thalidomide action (letter).  Nature. 1999;  400 419-420
    Search in Google Scholar
  • 32 Noguiera A C, Neubert R, Felies A, Jacob-Muller U, Frankus E, Neubert D. Thalidomide derivatives and the immune system. 6. Effects of two derivatives with no obvious teratogenic potency on the pattern of integrins and other surface receptors on blood cells of marmosets.  Life Sci. 1996;  58 337-348
    Search in Google Scholar
  • 33 Parman T, Wiley M J, Wells P G. Free radical-mediated oxidative damage in the mechanism of thalidomide terotegenicity.  Nat Med. 1999;  5 582-585
    Search in Google Scholar
  • 34 Reyes-Teran G, Sierra-Madero J G, Martinez del Cerro V, Arroyo-Figueroa H, Pasquetti A, Calva J J, Ruiz-Palacios G M. Effects of thalidomide on HIV-associated wasting syndrome: a randomized, double-blind, placebo-controlled clinical trial.  AIDS. 1996;  10 1501-1507
    Search in Google Scholar
  • 35 Sampaio E P, Kaplan G, Miranda A, Nery J AC, Miguel C P, Viana S M, Sarno E N. The influence of thalidomide on the clinical and immunologic manifestation of erythema nodosum leprosum.  J Infect Dis. 1993;  168 408-414
    Search in Google Scholar
  • 36 Saylan T, Saltik I. Thalidomide in the treatment of Behçet¿s syndrome.  Arch Dermatol. 1982;  118 536
    Search in Google Scholar
  • 37 Sheskin J. Thalidomide in the treatment of lepra reactions.  Clin Pharmacol Ther. 1965;  6 303-306
    Search in Google Scholar
  • 38 Sheskin J. The treatment of lepra reaction in lepromatous leprosy. Fifteen years’ experience with thalidomide.  Int J Dermatol. 1980;  19 318-322
    Search in Google Scholar
  • 39 Singhal S, Mehta J, Desikan R, Ayers D, Roberson P, Eddlemon P, Munshi N, Anaissie E, Wilson C, Dhodapkar M, Zeldis J, Barlogie B. Antitumor activity of thalidomide in refractory multiple myeloma.  N Eng J Med. 1999;  341 1565-1571
    Search in Google Scholar
  • 40 Soler R A, Howard M, Brink N S, Gibb D, Tedder R S, Nadal D. Regression of AIDS-Related Kaposi¿s sarcoma during therapy with thalidomide.  Clin Infect Dis. 1996;  23 501-503
    Search in Google Scholar
  • 41 Somers G F. Pharmacological properties of thalidomide(a-phtalimido glutarimide), a new sedative hypnotic drug.  Br J Pharmacol. 1960;  15 115-116
    Search in Google Scholar
  • 42 Stephens T D, Fillmore B J. Hypothesis: Thalidomide embryopathy-proposed mechanism of action.  Teratology. 2000;  61 189-195
    Search in Google Scholar
  • 43 Thomas D A, Aguayo A, Estey E, Albitar M, O¿Brian S, Giles F J, Beran M, Cortes J, Zeldis J, Keating M J, Barlogie B, Kantarjian H. Thalidomide as anti-antiangiogenesis therapy (RX) in refractory or relapsed Leukemias.  Blood. 1999;  92 702a (Suppl 1))
    Search in Google Scholar
  • 44 Vacca A, Ribatti D, Roncoll L, Ranieri G, Serio G, Silvestris F, Dammacco F. Bone marrow angiogenesis and progression in multiple myeloma.  Br J Haematol. 1994;  87 503-508
    Search in Google Scholar
  • 45 Venencie P Y, Saurat J H. Pyoderma gangrenosum in a child. Treatment with thalidomide (author’s transl).  Ann Pediatr Paris. 1982;  29 67-69
    Search in Google Scholar
  • 46 Vogelsang G B, Hess A D, Gordon G, Santos G W. Treatment and prevention of acute graft-versus-host disease with thalidomide in a rat model.  Transplantation. 1986;  41 644-647
    Search in Google Scholar
  • 47 Vogelsang G B, Farmer E R, Hess A D, Altamonte V, Beschorner W E, Jabs D A, Corio R L, Levin L S, Colvin O M, Wingard J R, Santos G W. Thalidomide for the treatment of chronic graft versus host disease.  N Eng J Med. 1992;  326 1055-1058
    Search in Google Scholar
  • 48 Weidenbach A. Totale Phokomelie.  Zentralbl für Gynäk. 1959;  81 2048-2052
    Search in Google Scholar
  • 49 Wulff C H, Hoyer H, Asboe-Hansen G, Brodthagen H. Development of polyneuropathy during thalidomide therapy.  Br J Dermatol. 1985;  112 475-480
    Search in Google Scholar

Korrespondenz

Dr. med. Gert Tuinmann

Universitätsklinikum Eppendorf

Martinistraße 52

20246 Hamburg

Phone: 040/42803-2311

Fax: 040/42803-2849

Email: tuinmann@uke.uni-hamburg.de